Pill to treat pancreatic cancer hailed as 'biggest breakthrough in decades'
Daraxonrasib showed promising tumour control in a small trial involving 61 people with advanced pancreatic cancer that had spread to other parts of the body. Tumours stopped growing in 90% of participants, and more than 60% saw tumours shrink or disappear. For about 8%, tumours became undetectable on CT scans. The results came during an average follow-up of 18 months. One year after starting treatment, 76.6% of participants were alive, compared with the 40–45% typically surviving a year after chemotherapy alone. These findings suggest the pill may give patients more time and may control disease more effectively than chemotherapy alone. Doctors caution that this is not yet a cure. They do not know how long the disease can stay controlled, and longer studies are needed to see whether cancers can remain in remission. The findings are encouraging, but more trials are required before daraxonrasib can be assessed for NHS use.
What did the trial of daraxonrasib show about pancreatic tumours?
Daraxonrasib showed promising tumour control in a small trial involving 61 people with advanced pancreatic cancer that had spread to other parts of the body. Tumours stopped growing in 90% of participants, and more than 60% saw tumours shrink or disappear. For about 8%, tumours became undetectable on CT scans.
The results came during an average follow-up of 18 months. One year after starting treatment, 76.6% of participants were alive, compared with the 40–45% typically surviving a year after chemotherapy alone. These findings suggest the pill may give patients more time and may control disease more effectively than chemotherapy alone.
Doctors caution that this is not yet a cure. They do not know how long the disease can stay controlled, and longer studies are needed to see whether cancers can remain in remission. The findings are encouraging, but more trials are required before daraxonrasib can be assessed for NHS use.
Of the 61 patients in the trial, how many had tumours stop growing, shrink or become undetectable?
The trial reported that tumours stopped growing in 90% of the 61 patients. That works out to about 55 people. More than 60% had tumours shrink or disappear, which is roughly 37 or more patients. About 8%—around five people—had tumours become undetectable on CT scans.
These groups are not separate: a tumour that becomes undetectable may also count as having stopped growing or shrinking. The article does not give exact patient counts for each result, so the percentages can only be translated into approximate numbers. It also does not say how many unique patients had at least one of these outcomes.
The figures describe different levels of response, from arrested growth to shrinkage and scans showing no detectable tumour. They are notable results in patients whose pancreatic cancer had already spread. However, the trial followed patients for an average of 18 months, and doctors do not yet know how long the benefit will last.
How did patients’ one-year survival with daraxonrasib compare with survival after chemotherapy alone?
One year after starting daraxonrasib, 76.6% of the trial participants were alive. The article compares this with the usual one-year survival of 40–45% among patients given chemotherapy alone. That difference is one reason researchers see the results as encouraging for a cancer with a very poor outlook.
The trial involved 61 people recently diagnosed with advanced pancreatic cancer that had spread to other parts of the body. Their tumours stopped growing in 90% of cases, while more than 60% had tumours shrink or disappear. These tumour responses help explain why the survival figure has attracted attention.
The comparison is not proof that daraxonrasib will improve survival for every patient. The article does not describe a direct comparison between randomly assigned treatment groups, and the average follow-up was 18 months. Doctors also do not know how long the disease can remain controlled. Longer studies are needed to assess remission and survival.
What does it mean for a tumour to be undetectable on a CT scan, and why is that not necessarily a cure?
A tumour described as undetectable on CT is not visible on that scan. This is a strong response, but it describes what imaging can show, rather than proving that no cancer remains anywhere in the body. In general medical practice, very small amounts of disease may be below a scan’s ability to detect them.
In the daraxonrasib trial, about 8% of patients’ tumours became undetectable on CT scans. The participants had advanced pancreatic cancer that had spread to other organs, and their average follow-up was 18 months. Some did not see the cancer return during that period, but the article does not say whether it will stay away longer.
Doctors have said the pill cannot yet be considered a cure. They do not know how long it can keep the disease at bay, and longer studies are planned to find out whether any cancers can be put into remission. A clear scan is encouraging, but it is not the same as confirmed lasting remission.
What is a KRAS inhibitor, and how can it slow cancer by blocking a mutation?
KRAS inhibitors are treatments aimed at altered forms of the KRAS gene or the proteins they produce. The article explains that certain KRAS mutations are found in most pancreatic cancers and drive tumour growth. Blocking their activity can interfere with that growth signal. This makes KRAS a target for treatment rather than treating cancer only by where it began.
Daraxonrasib is described as locking on to and shutting off certain mutations. In the trial, tumours stopped growing in 90% of the 61 patients; more than 60% saw tumours shrink or disappear. These results suggest that targeting the mutation can affect tumour behaviour, although they do not establish a cure.
The trial was in people with advanced pancreatic cancer, and doctors said they do not yet know how long the disease can stay controlled. The article also notes hopes for cancers with similar mutations, but more research is needed. Further trials must establish who benefits, how durable the response is, and whether the treatment can be assessed for NHS use.
Why is pancreatic cancer that has spread to other organs so difficult to treat?
Pancreatic cancer that has spread is advanced disease: the cancer is no longer confined to the pancreas. As a general medical point, cancer in several parts of the body is harder to treat with a local approach, so treatment needs to work throughout the body. The article does not give a detailed explanation of why pancreatic cancer is difficult to treat.
It does show how serious the outlook can be. Only about 3% of patients survive for five years when the disease has spread to other organs. Half of all people diagnosed with pancreatic cancer die within three months. In the daraxonrasib trial, all 61 participants had advanced cancer that had spread.
The results offer a possible way to control the disease: tumours stopped growing in 90% of trial participants, and more than 60% saw tumours shrink or disappear. Still, doctors say daraxonrasib is not yet a cure, and they do not know how long it can keep cancer at bay. Longer studies are needed.
How can the same KRAS mutation help drive cancers in different organs, and why might targeting it work across several cancer types?
A mutation is a change in a gene. The article says certain KRAS mutations drive tumour growth in most pancreatic cancers, and that other cancers can carry similar mutations. As a general explanation, a growth-driving mutation can affect how cells behave regardless of the organ where a cancer began. That can create a shared treatment target across different cancer types.
Daraxonrasib is a KRAS inhibitor: it locks on to and shuts off certain mutations. In its trial for advanced pancreatic cancer, tumours stopped growing in 90% of 61 patients, and more than 60% saw tumours shrink or disappear. The study did not test the pill across the other cancer types mentioned.
Researchers hope the approach could eventually help treat dozens of cancers with similar mutations. But that possibility is not yet established: Cancer Research UK chief executive Michelle Mitchell said more trials are needed before the treatment can be assessed for NHS use. Further research must show whether it works in other cancers and for which patients.
This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.
Read more in the JupiteX app
Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.
Or read more news on the web